Vanta Bioscience Ltd

VANTABIO

Watchlist

AI Mode

‌

Market Cap

₹ 15 Cr

P/E

—

‌

‌
‌

‌

‌
‌

Investment Checklist

How to read checklist?

Performance

UNDER PERFORMER

Valuation

UNDERVALUED

Growth

STABLE

Profitability

LOW MARGIN

Technicals

Bearish

Risk

HIGH RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Vanta Bioscience Limited specializes in preclinical activities, particularly in toxicology and safety assessments. It operates GLP-certified facilities delivering services to India and globally.

Founded in 2016, Vanta Bioscience offers risk assessment for chemical safety, catering to pharmaceuticals, cosmetics, and agrochemicals industries.

The company acquired and operates from a preclinical CRO facility in Chennai, acquired from Kemin Industries, providing extensive toxicology services.

Vanta Bioscience conducts both in vitro and in vivo toxicology studies under various international regulatory requirements.

In 2018-19, Vanta expanded its operations with subsidiaries such as Vanta Clinical Research Limited and Vayam Research Solutions Limited.

Sector

Healthcare

Industry

Biotechnology

Market Cap

15 Cr

Volatility

Low Risk

P/E Ratio

—

Industry P/E

74.2

PEG Ratio

—

P/B Ratio

1.0

52W High

44.49

52W Low

19.08

Sales CAGR

-79.84%

-50.60%

-39.68%

10Y

—

Profit CAGR

-54.36%

—

10Y

—

ROE

TTM

-23.51%

-12.08%

-6.02%

10Y

—

ROCE

TTM

-15.08%

-0.59%

2.19%

10Y

—

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
REMUS	755.65	890 Cr	30.81	3.48	0.10	10.92	16.89	7.42
INDOUS	125.05	251 Cr	14.83	2.89	0.00	19.49	16.44	14.40
VIVOBIOT	29.45	66 Cr	16.02	0.69	0.00	4.22	7.95	2.48
SHREEGANES	0.61	24 Cr	—	0.38	0.00	0.26	0.26	0.25
TRABI	2.72	22 Cr	—	2.34	0.00	-17.64	-3.52	-1.13
VANTABIO	20.49	15 Cr	—	1.01	0.00	-23.51	-15.08	-7.97
SCAGRO	21.75	13 Cr	31.52	4.46	0.00	14.14	16.25	4.15

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Dec 2022
Sales	2.82
Expenses	3.37
Operating Profit	-0.55
OPM %	-19.50
Other Income	0.01
Interest	2.48
Depreciation	1.31
Profit Before Tax	-2.47
Tax %	-3.64
Net Profit	-2.56
EPS in Rs	—

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	12	14	10	9.69	6.28	9.72	1.96
Expenses	9.15	9.77	6.09	6.22	8.67	8.41	6.22
Operating Profit	3.27	4.37	3.95	3.47	-2.39	1.31	-4.26
OPM %	26.35	30.89	39.31	35.80	-38.14	13.50	-216.78
Other Income	0.23	0.11	0.03	0.42	0.69	0.11	0.11
Interest	1.69	1.95	2.14	2.35	5.89	5.75	4.07
Depreciation	0.71	1.19	1.25	1.32	2.67	4.50	4.42
Profit Before Tax	1.10	1.34	0.59	0.23	-10	-8.83	-13
Tax %	36.74	24.52	23.91	41.03	-1.77	2.49	-5.23
Net Profit	0.70	1.01	0.45	0.13	-10	-8.61	-13
EPS in Rs	—	—	—	—	—	—	—
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	6.31	6.31	6.31	6.31	6.31	6.31	6.31
Reserves	16	17	18	18	11	8.89	4.11
Borrowings	12	16	32	40	57	61	70
Other Liabilities	4.59	9.57	14	17	10	9.24	5.37
Total Liabilities	39	49	70	81	85	85	86
Fixed Assets	18	21	29	36	57	54	55
CWIP	3.70	7.00	19	28	11	13	13
Investments	1.95	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	15	21	21	17	17	19	17
Total Assets	39	49	70	81	85	85	86

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity	-1.04	2.34	6.97	5.28	-0.63	2.68
Cash from Investing Activity	-5.73	-7.59	-22	-17	-5.91	-3.31
Cash from Financing Activity	9.94	2.17	18	9.53	6.41	0.69
Net Cash Flow	3.18	-3.07	2.46	-2.43	-0.13	0.06

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Sep 2020	Mar 2021	Sep 2021	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	69.93%	69.11%	69.00%	69.00%	69.36%	69.36%	69.36%	69.36%	69.36%	69.36%	72.81%	72.81%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	30.07%	30.89%	31.00%	31.00%	30.64%	30.64%	30.64%	30.64%	30.64%	30.64%	27.19%	27.19%
Total Shareholders	325	361	412	409	393	394	388	418	424	408	408	419

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
May 09, 2025	S chandra sekhar rao	Insider - Promoter	Acquisition	50.00	2.00 Cr	4,00,000	6.33
May 09, 2025	Dopesh raja mulakala	Insider - Promoter & Director	Acquisition	50.00	2.00 Cr	4,00,000	6.34

Projection

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Dec 2022
Sales	2.82
Expenses	3.37
Operating Profit	-0.55
OPM %	-19.50
Other Income	0.01
Interest	2.48
Depreciation	1.31
Profit Before Tax	-2.47
Tax %	-3.64
Net Profit	-2.56
EPS in Rs	—

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	12	14	10	9.69	6.28	9.72	1.96
Expenses	9.15	9.77	6.09	6.22	8.67	8.41	6.22
Operating Profit	3.27	4.37	3.95	3.47	-2.39	1.31	-4.26
OPM %	26.35	30.89	39.31	35.80	-38.14	13.50	-216.78
Other Income	0.23	0.11	0.03	0.42	0.69	0.11	0.11
Interest	1.69	1.95	2.14	2.35	5.89	5.75	4.07
Depreciation	0.71	1.19	1.25	1.32	2.67	4.50	4.42
Profit Before Tax	1.10	1.34	0.59	0.23	-10	-8.83	-13
Tax %	36.74	24.52	23.91	41.03	-1.77	2.49	-5.23
Net Profit	0.70	1.01	0.45	0.13	-10	-8.61	-13
EPS in Rs	—	—	—	—	—	—	—
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	6.31	6.31	6.31	6.31	6.31	6.31	6.31
Reserves	16	17	18	18	11	8.89	4.11
Borrowings	12	16	32	40	57	61	70
Other Liabilities	4.59	9.57	14	17	10	9.24	5.37
Total Liabilities	39	49	70	81	85	85	86
Fixed Assets	18	21	29	36	57	54	55
CWIP	3.70	7.00	19	28	11	13	13
Investments	1.95	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	15	21	21	17	17	19	17
Total Assets	39	49	70	81	85	85	86

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity	-1.04	2.34	6.97	5.28	-0.63	2.68
Cash from Investing Activity	-5.73	-7.59	-22	-17	-5.91	-3.31
Cash from Financing Activity	9.94	2.17	18	9.53	6.41	0.69
Net Cash Flow	3.18	-3.07	2.46	-2.43	-0.13	0.06

Overview

Detailed Summary

Vanta Bioscience Limited specializes in preclinical activities, particularly in toxicology and safety assessments. It operates GLP-certified facilities delivering services to India and globally.

Founded in 2016, Vanta Bioscience offers risk assessment for chemical safety, catering to pharmaceuticals, cosmetics, and agrochemicals industries.

The company acquired and operates from a preclinical CRO facility in Chennai, acquired from Kemin Industries, providing extensive toxicology services.

Vanta Bioscience conducts both in vitro and in vivo toxicology studies under various international regulatory requirements.

In 2018-19, Vanta expanded its operations with subsidiaries such as Vanta Clinical Research Limited and Vayam Research Solutions Limited.

Sector

Healthcare

Industry

Biotechnology

Market Cap

15 Cr

Volatility

Low Risk

P/E Ratio

—

Industry P/E

74.2

PEG Ratio

—

P/B Ratio

1.0

52W High

44.49

52W Low

19.08

Sales CAGR

-79.84%

-50.60%

-39.68%

10Y

—

Profit CAGR

-54.36%

—

10Y

—

ROE

TTM

-23.51%

-12.08%

-6.02%

10Y

—

ROCE

TTM

-15.08%

-0.59%

2.19%

10Y

—

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
REMUS	755.65	890 Cr	30.81	3.48	0.10	10.92	16.89	7.42
INDOUS	125.05	251 Cr	14.83	2.89	0.00	19.49	16.44	14.40
VIVOBIOT	29.45	66 Cr	16.02	0.69	0.00	4.22	7.95	2.48
SHREEGANES	0.61	24 Cr	—	0.38	0.00	0.26	0.26	0.25
TRABI	2.72	22 Cr	—	2.34	0.00	-17.64	-3.52	-1.13
VANTABIO	20.49	15 Cr	—	1.01	0.00	-23.51	-15.08	-7.97
SCAGRO	21.75	13 Cr	31.52	4.46	0.00	14.14	16.25	4.15